Payment overview · 2025
General Payments
$381.79
21 reported records · 14 companies
Healthcare provider profile · identity verified
Ronald Tyler Hebert, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAFAYETTE, LA · NPI 1003310897
Verified facts
What the public records show
CMS Open Payments records show Ronald Tyler Hebert, MD received $381.79 in general payments during 2025 across 21 reported records.
Lilly USA, LLC accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tudorza Pressair by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.73 | 13.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.45 | 12.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.33 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.62 | 9.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.18 | 8.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.10 | 6.8% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $24.53 | 6.4% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $21.28 | 5.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.21 | 5.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.98 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.87 | 5.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.55 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.36 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.60 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.79 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.58 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.63 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 158 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
158 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 318 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 280 | 50 |
| Alprazolam | Alprazolam | 244 | 41 |
| Trazodone Hcl | Trazodone Hcl | 231 | 60 |
| Losartan Potassium | Losartan Potassium | 210 | 61 |
| Celecoxib | Celecoxib | 202 | 70 |
| Carvedilol | Carvedilol | 200 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 63 |
| Metformin Hcl | Metformin Hcl | 179 | 49 |
| Lisinopril | Lisinopril | 176 | 60 |
| Omeprazole | Omeprazole | 175 | 60 |
| Gabapentin | Gabapentin | 174 | 55 |
| Furosemide | Furosemide | 172 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 43 |
| Mounjaro | Tirzepatide | 158 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 53 |
| Glimepiride | Glimepiride | 132 | 46 |
| Montelukast Sodium | Montelukast Sodium | 127 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 29 |
| Alendronate Sodium | Alendronate Sodium | 107 | 32 |
| Simvastatin | Simvastatin | 105 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 33 |
| Prednisone | Prednisone | 98 | 47 |
| Pregabalin | Pregabalin | 96 | 19 |
| Clonazepam | Clonazepam | 94 | 17 |
| Potassium Chloride | Potassium Chloride | 92 | 34 |
| Ozempic | Semaglutide | 87 | 18 |
| Ezetimibe | Ezetimibe | 83 | 25 |
| Tramadol Hcl | Tramadol Hcl | 81 | 29 |
| Famotidine | Famotidine | 80 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 26 |
| Eliquis | Apixaban | 79 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 75 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 21 |
| Lorazepam | Lorazepam | 72 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 38 |
| Meloxicam | Meloxicam | 69 | 19 |
| Bupropion Xl | Bupropion Hcl | 68 | 22 |
| Azithromycin | Azithromycin | 67 | 60 |
| Nifedipine Er | Nifedipine | 66 | 13 |
| Sertraline Hcl | Sertraline Hcl | 66 | 21 |
| Allopurinol | Allopurinol | 64 | 25 |
| Finasteride | Finasteride | 63 | 18 |
| Valsartan | Valsartan | 63 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 14 |
| Mirtazapine | Mirtazapine | 60 | 12 |
| Azelastine Hcl | Azelastine Hcl | 58 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 17 |
| Diazepam | Diazepam | 58 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 11 |
| Farxiga | Dapagliflozin Propanediol | 50 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 22 |
| Sucralfate | Sucralfate | 49 | 12 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 35 |
| Ondansetron Odt | Ondansetron | 48 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 17 |
| Clonidine | Clonidine | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Primidone | Primidone | 44 | 14 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 17 |
| Cephalexin | Cephalexin | 40 | 27 |
| Metformin Hcl Er | Metformin Hcl | 40 | 13 |
| Methocarbamol | Methocarbamol | 40 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 12 |
| Fluconazole | Fluconazole | 39 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 16 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Jardiance | Empagliflozin | 34 | 12 |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | 14 |
| Levofloxacin | Levofloxacin | 31 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 24 |
| Spironolactone | Spironolactone | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Cefdinir | Cefdinir | 27 | 24 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.79 · 21 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, Azstarys, COMIRNATY, EVENITY, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Wegovy, Xelstrym, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error